

Effective: January 1, 2023

Prior Authorization Required If <u>REQUIRED</u> , submit supporting clinical documentation pertinent to service request.	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
--	---

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products; Fax 617-673-0988

☐ Tufts Health Plan Commercial products; Fax 617-673-0988

CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

Public Plans Products

☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); Fax 617-673-0988

☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; Fax 617-673-0988

☐ Tufts Health RITogether – A Rhode Island Medicaid Plan; Fax 617-673-0988

☐ Tufts Health One Care* – A Medicare-Medicaid Plan (a dual eligible product); Fax 617-673-0956

*The MNG applies to Tufts Health One Care members unless a less restrictive LCD or NCD exists

Senior Products

☐ Harvard Pilgrim Health Care Stride Medicare Advantage; Fax 617-673-0956

☐ Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product); Fax 617-673-0956

☐ Tufts Medicare Preferred HMO, (a Medicare Advantage product); Fax 617-673-0956

☐ Tufts Medicare Preferred PPO, (a Medicare Advantage product); Fax 617-673-0956

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration (FDA) Approved Indications:

- **Avastin Ophthalmic Conditions Compendial Uses:**
 - Age related macular degeneration
 - Diabetic macular edema
 - Macular retinal edema

NOTE: Providers and Members enrolled with Harvard Pilgrim Health Care may reference the HPHC/OncoHealth guideline for coverage of oncology-related indications, located at <https://oncohealth.us/medicalpolicies/harvardpilgrim/>

Clinical Guideline Coverage Criteria

Initial Authorization:

The Plan may cover Avastin (bevacizumab) when all the following clinical criteria is met:

1. Member has documented diagnosis of one (1) of the following:
 - a. Age related macular degeneration
 - b. Diabetic macular edema
 - c. Macular retinal edema

Reauthorization:

The Plan may reauthorization Avastin (bevacizumab) when all the following criteria are met:

- 1. Member is experiencing a clinical benefit to therapy or who have not experienced an unacceptable toxicity

Limitations

- Authorizations will be provided for 12 months.

Codes

The following code(s) require prior authorization:

Table 1: HCPCS Codes

HCPCS Codes	Description
J9035	Injection, bevacizumab, 10 mg

References:

- 1. Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; November 2021.
- 2. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>
- 3. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium® - bevacizumab. Accessed 3/2023.

Approval And Revision History

March 14, 2023: Reviewed by Pharmacy and Therapeutics Committee (P&T)

March 15, 2023: Reviewed by the Medical Policy Approval Committee (MPAC)

Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member’s benefit document, and in coordination with the Member’s physician(s) on a case-by-case basis considering the individual Member’s health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member’s benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.

